Third-line Chemotherapy

Third-Line Chemotherapy is a chemotherapeutic regimen administered after the failure of two prior lines of therapy, distinguished by its positioning as the subsequent treatment option in a sequence of palliative cancer interventions.

333

Publications

16.5K

Citations

2.7K

Authors

907

Institutions

Publications per year

2017–2026

100

Parents

Palliative Chemotherapy

Publications

333

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Tim Maughan, Richard Adams, Christopher G. Smith et al. · The Lancet · 2011 · 967 citations

Medicine, Oncology, Pharmacology +12

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Peter Thuss‐Patience, Albrecht Kretzschmar, Dmitry Bichev et al. · European Journal of Cancer · 2011 · 615 citations

Medicine, Oncology, Pharmacotherapy +13

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui et al. · Journal of Clinical Oncology · 2013 · 559 citations

Medicine, Oncology, Pharmacology +10

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem et al. · Annals of Oncology · 2018 · 503 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With <i>BRCA1</i> and <i>BRCA2</i> Mutations

David S.P. Tan, Christian Rothermundt, Karen Thomas et al. · Journal of Clinical Oncology · 2008 · 472 citations

Medicine, Gynecology, Oncology +17

1–5 of 333

Authors

2.7K

NB
Narikazu Boku
National Cancer Center Hospital East, Japan
7 publications · 1.2K citations
7
h-index
IJ
Ian Judson
Royal Marsden Hospital, United Kingdom
5 publications · 767 citations
5
h-index
DS
Daniele Santini
Università Campus Bio-Medico, Italy
5 publications · 360 citations
5
h-index
SM
Satoshi Morita
Kyoto University, Japan
4 publications · 721 citations
4
h-index
AS
Armando Santoro
Humanitas University, Italy
4 publications · 125 citations
4
h-index

1–5 of 2.7K

Institutions

907

1–8 of 907

Venues

Journal of Clinical Oncology
28 publications · 3.4K citations
21
h-index
PubMed
Repository · 32 publications · 943 citations
18
h-index
Annals of Oncology
13 publications · 1.6K citations
13
h-index
British Journal of Cancer
BJC · 12 publications · 695 citations
12
h-index
American Journal of Clinical Oncology
AJCO · 9 publications · 221 citations
9
h-index

1–5